Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
doi 10.17749/2070-4909.2019.12.4.279-290
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IRBIS

Related search

Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications

Frontiers in Genetics
GeneticsMolecular Medicine
2020English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer

Therapeutic Advances in Medical Oncology
Oncology
2018English

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

Clinical and Economic Analysis of Effectiveness of Everolimus in the Treatment of HR+, HER2- Advanced Breast Cancer in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy